Related Experiment Video

Updated: Mar 13, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.5K

Hemolysis induced by PMIVSD occluder

D Sheshagiri Rao1, Ramachandra Barik2, Akula Siva Prasad3

  • 1Professor, Department of Cardiology, Nizam's Institute of Medical Sciences, Hyderabad 500082, Telengana, India.

Indian Heart Journal
|October 19, 2016
PubMed

Insights

Hemolysis after transcatheter closure of post-myocardial infarction ventricular septal defect (PMIVSD) is rare. This case highlights the importance of monitoring for complications like hemolysis following device closure.

Area of Science:

  • Cardiology
  • Medical Devices
  • Hematology

Background:

  • Transcatheter closure is a common treatment for various cardiac defects.
  • Hemolysis, the premature destruction of red blood cells, can occur with intracardiac devices.
  • Post-myocardial infarction ventricular septal defect (PMIVSD) closure presents unique challenges.

Observation:

  • A patient developed hemolysis after transcatheter closure of a PMIVSD using an atrial septal occluder.
  • While device closure was technically successful, hemolysis emerged as a complication.
  • This complication, though infrequent, necessitates careful patient monitoring.

Findings:

  • Hemolysis associated with PMIVSD device closure is uncommon compared to other cardiac interventions.
  • The study presents a case demonstrating hemolysis following PMIVSD closure with an atrial septal occluder.
  • Close follow-up is crucial for managing potential complications post-procedure.

Implications:

  • This case underscores the need for vigilance regarding hemolysis after PMIVSD device closure.
  • Management strategies may include conservative follow-up or, in rare cases, device retrieval or long-term transfusion.
  • Further research into the mechanisms and prevention of hemolysis in this context is warranted.
Keywords:
Atrial septal occluder (ASO)HemolysisPost-myocardial infarction ventricular septal defect (PMIVSD)Transcathetor closure (TCC)

More Related Videos

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

2.7K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
413
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
842
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.1K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
833
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
955
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
493